Cipla misses Q4 profit estimates on weak U.S. sales
Cipla misses analysts’ average estimate of ₹7.05 billion reporting a poorer Q4 profit. File | Photo Credit: AP Cipla, third-largest drugmaker by revenue, reported a weaker-than-expected fourth quarter profit on Wednesday (May 13, 2026), as sharp weakness in its U.S. business and higher costs outweighed strong domestic demand. The drugmaker’s consolidated net profit fell 54.6%…
Read More “Cipla misses Q4 profit estimates on weak U.S. sales” »